Objective. To evaluate the expression profiles of cell-free plasma miRNAs in SSc and to characterize their correlation with disease subgroups (lcSSc and dcSSc) and with autoantibody profiles.
In the present study, we therefore examined a Swedish cohort of SSc patients to explore correlation of plasma miRNAs with phenotype and autoantibody profiles. Our hypothesis is that patient subsets with different prognoses, for example, represented by different autoantibody profiles, are characterized by specific miRNA profiles.
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Patients and methods
Patients
We included 95 SSc patients (82 women, 13 men) who received care at the Systemic Sclerosis Unit, Department of Rheumatology, Skåne University Hospital in Lund, Sweden.
The patients were enrolled between 31 March 1989 and 1 January 2012. The clinical data are shown in Table 1 . The patients were chosen at random from the whole cohort in order to fulfil the distribution of four groups (n = 20 each for ATA/ARA/RNP and n = 35 for ACA) defined 
Clinical assessment
Clinical and routine paraclinical data were obtained under identical conditions and as close as possible (usually within 1 week) to the blood sampling date as previously described [8, 9] . The modified Rodnan skin score was evaluated by standardized palpation of the skin [10].
Oesophageal involvement was defined as distal hypomotility on cine-radiography.
Radiological lung involvement was defined as basal interstitial fibrosis on plain chest X-ray or high-resolution CT [9] . Lung function tests included assessment of vital capacity by dry spirometry and diffusing capacity for carbon monoxide by single-breath test. Values are listed as percentage of predicted (p%). Cardiac involvement was assessed by radiological examination, 12-lead ECG and Doppler cardiography and defined as pericarditis, abnormal ECG or cardiomegaly. Systolic pulmonary artery pressure of ≥40 mmHg by Doppler cardiography was regarded as pathologically raised. Muscle involvement was defined as proximal muscle weakness or serum creatinine kinase levels ≥3 times above the upper limit of normal (3.3 µkat/l). Joint involvement was defined as palpable synovitis. Renal involvement was defined as decreased glomerular filtration rate (GFR, <70% of predicted) either by Table S1 , available at Rheumatology Online). The mixture of three synthetic cel-miRNAs was spiked into the lysis buffer for use as technical normalization [4] .
Data handling and statistical analyses
The demographic and paraclinical data were analysed for differences within patient groups with STATISTICA v.12 (StatSoft, Tulsa, OK, USA). Data are depicted as median (IQR).
Pearson's Chi-square test was used when applicable. Differences in frequencies between groups were evaluated by Fisher's exact test. For the qRT-PCR data average, quantitation cycle (Cq) values >30 were removed from the dataset. The Cq values were then normalized using levels of spike-in controls and row means as described [4] (supplementary data, available at Rheumatology Online). The normalized miRNA Cq variables were used for autoantibody group comparisons (Kruskal-Wallis with Dunn's post-test for comparing between the four antibody groups) and in univariate comparisons (Mann-Whitney), with P = 0.05 as the significance threshold using GraphPadPrism v. 5.0 (GraphPad Software Inc., San Diego, CA, USA). Correction for multiple comparisons was achieved by the false discovery rate method [13] . Heat maps were generated by Genesis, release 1.7.6 [14] .
For further statistical analyses, data were converted to Z-scores (mean = 0, s.d. = 1) and analysed in R, a statistical programming environment (http://www.r-project.org). All variables and groups, as well as residuals in multiple linear regression analyses, were analysed for normal distribution and tested by the Shapiro-Wilk test. W-values >0.93 were accepted as normally distributed. Regression analyses were performed with the exclusion of data from 17 patients who were either on dialysis or had treatment other than prednisolone, leaving n = 78 patients for the analyses. The miRNA expression profiles that were associated with the two SSc disease subgroups and the four autoantibody groups (dependent variables) were used for modelling, based on logistic regression. We assessed multicollinearity (variables that do not significantly contribute further to the model fit) by variance inflation factor analysis. Variables with variance inflation factor >10 were eliminated from further analysis. Finally, the remaining explanatory variables were used to build and analyse the logistic regression models. We applied the mean difference in miRNA expression for each of the clinical phenotypes and autoantibody groups as a means of removing uninformative miRNA expression profiles from our model and of identifying interesting miRNAs to be used for our model. We included independent variables that had a P-value of 0.5 when regressed, individually, with the dependent variable (variable to be predicted) in the model, leading to a broader miRNA expression panel than the univariate analysis.
Results
Circulating miRNAs and patient set-up
For this study, a Swedish cohort of 95 patients with SSc was employed. The demographic data are depicted in Table 1 . A total of 45 mature miRNAs were chosen for analysis, based on previous studies and reports of circulating miRNAs in SSc and SLE patients [4, 5, 15] . Based on the criterion that the miRNA should be detectable in every one of the 95 samples, 36 of these miRNAs were included in the final data analysis. The normalized miRNA expression levels were scrutinized for associations with sample age, since a possible link between miRNA expression level and sample age had been suggested in our previous study [5] . No statistically significant associations between miRNA expression level and sample age, however, were detectable in the present cohort. The normalized miRNA data were analysed for associations with SSc disease phenotype and autoantibody groups. In a second step, data analyses relating miRNA expression to organ involvement as well as logistic regression analysis were performed on 78 patients without DMARD or dialysis treatment. We reasoned that miRNA levels in DMARD-naive individuals would mirror disease-related conditions in a more straightforward way. Initial enquiries did not show any significant effect of prednisolone on miRNA expression. Patients on concomitant prednisolone treatment were therefore admitted to the logistic regression analysis. miRNA profiles and disease phenotype Six miRNAs were significantly different between the lcSSc and dcSSc groups in the univariate analysis (Fig. 1) . Four of these miRNAs (miR-223, -181b, -342-3p and -184) remained significant after correcting for multiple comparisons (false discovery rate <0.05) ( Table 2) (Fig. 2) . Also, 11 miRNAs were differently expressed between the antibody groups ( Table 2 ). Nine of these 11 miRNAs showed significant differential expression using Dunn's post-test to compare pairs of groups (Table   2Fig . 3) and 5 miRNAs (miR-409-3p, -184, -92a, -29a and -101) remained significantly differently expressed after adjusting for multiple comparisons (Table 2) miRNA and organ involvement We tested whether organ involvement would be associated with specific miRNA profiles in DMARD-naive patients. Univariate analysis showed an association of increased miR-101 and decreased miR-92a levels with pulmonary fibrosis (P = 0.01 and 0.027, respectively).
However, none of the associations remained significant after adjustment for multiple comparisons.
Discussion
Our study shows that miRNAs are differentially expressed between lcSSc and dcSSc subgroups and that the presence of specific autoantibodies is accompanied by the occurrence of particular miRNA profiles. The major findings are summarized in Fig. 4 .
SSc is recognized to be a heterogeneous disease, and the notion has been put forward that SSc possibly consists of distinct disease entities [16] . In agreement with this, our results show that the levels of specific circulating miRNAs clearly differ between the clinical phenotypes and autoantibody groups, as confirmed by a number of statistical methods. In particular, patients with ACA stand out. Half of the ACA-positive patients were grouped together in the cluster analysis. ROC analysis showed a high predictive value for ACA patients, suggesting a robust miRNA expression profile in relation to the presence of ACAs. In addition, ROC analysis showed good predictive values for patients with ATA and for the disease phenotypes. Specific miRNA profiles are therefore suggested to mirror the grouping of patients according to these classifications. Further, correlation analyses showed clear miRNA co-expression patterns beyond antibody grouping. This suggests that patients may also be linked at a molecular level through their circulating miRNA profiles in addition to their clinical phenotypes and autoantibody profiles.
MiR-409-3p expression levels are increased in ACA, compared with the other three autoantibody groups. We have previously shown that miR-409-3p levels were higher in another cohort of SSc patients (of which 41% were ACA positive) vs normal controls [5] .
Thus, the combined information suggests an increase of this miR-409-3p in lcSSc. However, it is not possible to determine the absolute levels of specific miRNAs in comparison with healthy controls in the present study because healthy controls were not included. Also, there is no interstudy standardization and no standard curves included in the miRNA assays, and the row mean normalization is based on different sets of miRNAs in the two studies. No data are yet available on the biological effect of miR-409-3p with regard to pathogenesis in SSc.
MiR-184 expression levels were higher in dcSSc and in the autoantibody groups ATA and ARA. Proinflammatory cytokines such as IL-22 induce keratinocytic miR-184 expression (which in turn inhibits argonaute-2, a protein that is important for mRNA repression by miRNAs) and thus potentially lead to increased protein expression [17] . So far, however, no data can be found on miR-184 with regard to fibrosis development or angiogenesis in general and to SSc in particular.
MiR-92a levels were lower in patients with ATA and RNP compared with the ACA and ARA groups. Patients with ATA and RNP have an increased risk of developing pulmonary fibrosis compared with patients with ACA and ARA. Indeed, the presence of ACA predicts an absence of pulmonary fibrosis [18] . Interestingly, miR-92a was decreased in patients with pulmonary fibrosis. Even though the association was not significant when adjusted for multiple comparison, low miR-92a levels may be associated with pulmonary fibrosis, as our inclusion criteria of visible fibrosis on high-resolution CT was not adjusted for the extent of fibrosis. Patients with mild fibrosis may dilute the analysis. MiR-92a is downregulated in lung tissue of patients with idiopathic pulmonary fibrosis [19] . Hypothetically, low miR-92 levels could therefore play a part in the development of pulmonary fibrosis in patients with ATA and RNP. In our previous study, miR-92a levels in plasma were decreased in SSc compared with healthy controls [5] , whereas, in contrast, one other previous study presented increased miR-92a levels in sera of SSc patients [20] .
A limitation of this explorative study is the cross-sectional design. Data should therefore be interpreted with some caution until future verification in validation cohorts. A second limitation is the comparatively small number of patients analysed for miRNA expression.
However, the cohort is well characterized and includes analysis of 78 patients without DMARD treatment. Expression of miRNAs in this group should therefore reflect disease pathogenesis.
Conclusion
To the best of our knowledge, this is the first study to link expression levels of specific circulating plasma miRNAs to clinical phenotypes and autoantibody profiles in SSc. = disease modifying anti rheumatic drug; ESR = erythrocyte sedimentation rate; lcSSc = limited cutaneous SSc; IgG = immunoglobulin G; mRss = modified Rodnan skin score; Pearson Chi-square: a P < 0.05, b P < 0.01, c P < 0.001; Kruskal Wallis: * P < 0.05, ** P < 0.01, *** P < 0.001 The figure summarizes relations between microRNAs and antibody subgroups and disease phenotypes that were identified in this study. 
